BACKGROUND: In the general population, low serum @entity1760 levels are associated with poor outcomes and @entity204 . While limited data suggest that low baseline @entity1760 levels may be associated with higher mortality in hemodialysis (HD) @entity1 , the impact of changes in @entity1760 levels over time is unknown. STUDY DESIGN: We examined the association of time-varying serum @entity1760 levels with all-cause mortality using multivariable time-varying survival models adjusted for clinical characteristics and other time-varying laboratory measures. SETTING _ @entity1 : 9,359 maintenance HD @entity1 treated in a large dialysis organization between 2007 and  2011. PREDICTOR: Time-varying serum @entity1760 levels across 5 @entity1760 increments (<1.8, 1.8-<2.0, 2.0-<2.2, 2.2-<2.4, and  >= 2.4mg/dL). OUTCOME: All-cause mortality. RESULTS: 2,636 individuals died over 5 years. Time-varying serum @entity1760 levels  < 2.0mg/dL were associated with higher mortality after adjustment for demographics and comorbid conditions, including @entity101 , @entity6 , and @entity5 (reference: @entity1760 , 2.2-<2.4mg/dL): adjusted HRs for serum @entity1760 level  < 1.8 and 1.8 to  <2.0mg/dL were 1.39 (95% CI, 1.23-1.58; P<0.001) and 1.20 (95% CI, 1.06-1.36; P=0.004), respectively. Some associations were attenuated to the null after incremental adjustment for laboratory test results, particularly serum albumin. However, among patients with serum albumin measurements, low albumin level (<3.5g/dL) and @entity1760 level  < 2.0mg/dL were associated with an additional @entity204 risk (adjusted HR, 1.17; 95% CI, 1.05-1.31; P=0.004), whereas @entity1 with high serum albumin levels (>= 3.5g/dL) exhibited @entity204 (adjusted HRs of 0.53 and 0.53 [P <=0.001] for @entity1760  < 2.0 and  >= 2.0mg/dL, respectively; reference: albumin  < 3.5g/dL and @entity1760  >=  2.0mg/dL). LIMITATIONS: Causality cannot be determined, and residual confounding cannot be excluded given the observational study design. CONCLUSIONS: Lower serum @entity1760 levels are associated with higher mortality in HD @entity1 , including those with @entity4988 . Interventional studies are warranted to examine whether correction of @entity1272 ameliorates adverse outcomes in this population.

XXXX and Mortality in Incident Hemodialysis  @entity1 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity4988 :: ('MESH:D034141', 'Disease') :: ['hypoalbuminemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity1272 :: ('MESH:C537153', 'Disease') :: ['hypomagnesemia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['low death risk', 'death'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity1272 :: (MESH:C537153,Disease) :: ['Hypomagnesemia']
